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The mechanisms underlying the pathogenicity of CCR5-restricted (R5) human immunodeficiency virus type-1 (HIV-1) strains are
incompletely understood. Acquisition or enhancement of macrophage (M)-tropism by R5 viruses contributes to R5 HIV-1 pathogenesis. In
this study, we show that M-tropic R5 viruses isolated from individuals with acquired immunodeficiency syndrome (late R5 viruses) require
lower levels of CD4/CCR5 expression for entry, have decreased sensitivity to inhibition by the entry inhibitors TAK-779 and T-20, and have
increased sensitivity to neutralization by the Env MAb IgG1b12 compared with non-M-tropic R5 viruses isolated from asymptomatic,
immunocompetent individuals (early R5 viruses). Augmenting CCR5 expression levels on monocyte-derived macrophages via retroviral
transduction led to a complete or marginal restoration of M-tropism by early R5 viruses, depending on the viral strain. Thus, reduced CD4/
CCR5 dependence is a phenotype of R5 HIV-1 associated with M-tropism and late stage infection, which may affect the efficacy of HIV-1
entry inhibitors.
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Progression of human immunodeficiency virus type 1
(HIV-1) infection from early, asymptomatic stages of
disease to acquired immunodeficiency syndrome (AIDS)
is associated with a switch in viral coreceptor specificity0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: gorry@burnet.edu.au (P.R. Gorry).from CCR5 using (R5) viral strains to those able to use
CXCR4 (X4) or both coreceptors (R5X4) in 40–50% of
infected adults (Bjorndal et al., 1997; Connor et al., 1997;
Karlsson et al., 1994; Koot et al., 1993; Tersmette et al.,
1989) (reviewed in de Roda Husman and Schuitemaker,
1998). However, X4 or R5X4 variants are absent in 50–
60% of HIV-1-infected individuals who progress to AIDS
(de Roda Husman et al., 1999; Jansson et al., 1996, 1999;
Karlsson et al., 2004; Koning et al., 2003) (reviewed in
Gorry et al., 2005). Therefore, the persistence of an
exclusive R5 viral population in vivo is sufficient to cause05) 384 – 398
L. Gray et al. / Virology 337 (2005) 384–398 385immunodeficiency in the majority of HIV-1-infected indi-
viduals who progress to AIDS.
Whilst much effort has been directed towards under-
standing the molecular basis of pathogenicity of late-
emerging X4 and R5X4 viruses (Glushakova et al., 1995,
1998; Picchio et al., 1998) (reviewed in de Roda Husman
and Schuitemaker, 1998), the molecular mechanisms
underlying the pathogenicity of R5 HIV-1 strains are
incompletely understood (Gorry et al., 2005). R5 viruses
are intrinsically cytopathic but exert pathogenic effects that
are distinct from those of X4 or R5X4 viruses (Fais et al.,
1999; Grivel and Margolis, 1999; Harouse et al., 1999).
R5 HIV-1 strains isolated from patients with AIDS
(hereafter referred to as late R5 viruses) have enhanced
macrophage (M)-tropism (Li et al., 1999; Tuttle et al.,
2002) and cause increased levels of CD4+ T cell death
(Kwa et al., 2003) compared with R5 HIV-1 strains
isolated from asymptomatic individuals (hereafter referred
to as early R5 viruses). Late R5 viruses were shown to
have increased in vivo cytopathicity in HIV-1-infected
SCID-hu mice compared with early R5 viruses by one
study (Scoggins et al., 2000), although this conclusion was
not reached by other in vivo and ex vivo studies
(Berkowitz et al., 1999; Kreisberg et al., 2001). Late R5
viruses have decreased sensitivity to inhibition by the h-
chemokine RANTES (regulated on activation, normally T-
cell-expressed and -secreted) compared with early R5
viruses (Jansson et al., 1999; Karlsson et al., 2004; Koning
et al., 2003). Recent evidence suggests that decreased
RANTES sensitivity is attributed to an increased flexibility
of the R5 envelope glycoproteins (Env) that subsequently
alters the mode and efficiency of CCR5 binding (Karlsson
et al., 2004). Together, these findings provide evidence that
late R5 viruses have intrinsic properties distinguishing
them from early R5 viruses which may enhance their
cytopathic effects, and that these properties are likely to be
linked to Env conformations that enhance CD4 and/or
CCR5 interactions.
The coreceptor specificity of primary HIV-1 isolates is
frequently used to define HIV-1 tropism (reviewed in
Kedzierska et al., 2003). For example, R5 viruses are
often collectively grouped as M-tropic viral strains.
However, several studies have failed to establish a strict
correlation between CCR5 usage and M-tropism of HIV-1
(Cheng-Mayer et al., 1997; Cunningham et al., 2000;
Dittmar et al., 1997; Hung et al., 1999). In fact, further
studies have demonstrated the presence of non-M-tropic
R5 viruses, which were replication competent in primary
CD4+ T cells but which could not productively infect
macrophages (Gorry et al., 2001; Li et al., 1999). Thus,
while CCR5 may be the main coreceptor for HIV-1 entry
in macrophages, not all R5 viruses are M-tropic. In
addition, some highly M-tropic primary HIV-1 strains use
CXCR4 for entry in macrophages and microglia (Ancuta
et al., 2001; Gorry et al., 2001; Koning et al., 2001; Naif
et al., 2002; Ohagen et al., 2003; Singh et al., 2001; Yi etal., 1998, 1999). Furthermore, the principal source of
plasma virus in macaques infected with a simian–human
immunodeficiency virus (SHIV) strain that uses CXCR4
exclusively for virus entry is the tissue macrophage
(Igarashi et al., 2001, 2003). Therefore, the viral
determinants that underlie HIV-1 tropism for macrophages
are significantly more complex than the coreceptor
specificity of the virus.
Macrophages express lower levels of CD4, CCR5, and
CXCR4 on the cell surface compared with CD4+ T cells
(Lewin et al., 1996; Ometto et al., 1999; Wang et al., 2002),
and low levels of these receptors expressed on macaque
macrophages can restrict infection of some non-M-tropic R5
HIV-1 and X4 simian immunodeficiency virus (SIV) strains
(Bannert et al., 2000; Mori et al., 2000). Furthermore, the
level of CCR5 expression and CCR5 density can determine
the level of susceptibility of human macrophages to
infection by M-tropic R5 HIV-1 strains (Fear et al., 1998;
Kuhmann et al., 2000; Rana et al., 1997; Reynes et al.,
2001; Tuttle et al., 1998). Undifferentiated monocytes,
which are refractory to infection by R5 HIV-1 viruses,
become susceptible to infection by M-tropic R5 viruses
upon differentiation concomitant with an increase in CCR5
expression levels (Collman et al., 1989; Di Marzio et al.,
1998; Eisert et al., 2001; Fear et al., 1998; Naif et al., 1998;
Neil et al., 2001; Rich et al., 1992; Sonza et al., 1996; Tuttle
et al., 1998). Although restrictions to replication of R5
viruses in monocytes have been identified both pre- and
post-reverse transcription (Eisert et al., 2001; Neil et al.,
2001; Sonza et al., 1996; Triques and Stevenson, 2004), the
major barrier to productive infection of differentiated
monocyte-derived macrophages (MDM) and cultured
microglia by non-M-tropic R5 HIV-1 strains is prior to
reverse transcription (Gorry et al., 2001; Li et al., 1999).
However, studies with identical twins showed that host cell
genetics have an effect on the level of productive infection
of M-tropic R5 viruses in MDM that is not related to CCR5
expression levels, and is exerted between viral entry and
reverse transcription (Cunningham et al., 2000; Naif et al.,
1999). Thus, levels of CD4 and/or CCR5 expression as well
as post-entry stages of the HIV-1 replication cycle may be
bottlenecks for productive infection of macrophages by R5
viruses.
The present study sought to better understand the
biological properties of late-emerging primary R5 viruses
that are important for M-tropism and R5 HIV-1 pathogen-
esis. We demonstrate two distinct phenotypes of primary R5
viruses; late, M-tropic R5 viruses have reduced dependence
on CD4/CCR5 levels for entry and have reduced sensitivity
to entry inhibitors TAK-779 and T-20. In contrast, early,
non-M-tropic R5 viruses require comparatively higher
levels of CD4/CCR5 for entry and are highly sensitive to
inhibition by TAK-779 and T-20. Thus, enhancing CD4/
CCR5 interactions may be a means by which R5 viruses
increase their virulence and may affect the efficacy of HIV-1
entry inhibitors.
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Coreceptor usage
HIV-1 isolates were characterized for their ability to use
CCR5, CXCR4, or alternative coreceptors for entry (Table
1). The X4, R5, and R5X4 strains NL4-3, ADA, and 89.6,
respectively, were used as controls. NL4-3 used CXCR4
and Apj; ADA used CCR3, CCR5, CCR8, CX3CR1,
Strl33, Gpr15, Gpr1, and Apj; and 89.6 used CCR2b,
CCR3, CCR5, CXCR4, and Apj as coreceptors for virus
entry, as described in previous studies (Churchill et al.,
2004; Gorry et al., 2001, 2002b; Lawson et al., 2004). Early
and late viruses used CCR5 as the sole coreceptor for entry,
except NB7 where additional minor usage of CCR3 was
evident. None of the viruses used CCR5 for entry in the
absence of CD4 (data not shown). Thus, none of the
primary HIV-1 viruses were CD4-independent, and all used
CCR5 as the principal coreceptor for virus entry.
Replication kinetics
We examined the capacity of the early and late R5
viruses to replicate in MDM, PBMC, and the JC53 cell line.
ADA was used as a control and replicated to high levels in
the three cell types (Figs. 1A–C). Late R5 viruses replicated
to high levels in all cell types, similar to ADA (Figs. 1G–I).
Early R5 viruses replicated to high levels in JC53 cells (Fig.
1F), to moderately high levels in PBMC with delayed
replication kinetics (Fig. 1E), but were unable to replicate or
replicated poorly in MDM (Fig. 1D). Thus, the early R5
viruses have impaired replication capacity in MDM and can
be classified as non-M-tropic R5 viruses as described
previously (Gorry et al., 2001). JC53 cells have higher
levels of CD4/CCR5 cell surface expression than PBMCTable 1
Coreceptor usage by primary and reference HIV-1 isolates
Coreceptor usage
CD4 only CCR2b CCR3 CCR5 CCR8
Controls
NL4-3     
ADA   ++ +++ +
89.6  + ++ +++ 
Early R5 viruses
NB23    +++ 
NB24    +++ 
NB25    +++ 
NB27    +++ 
Late R5 viruses
NB2    +++ 
NB6    +++ 
NB7   + +++ 
NB8    +++ 
Coreceptor usage of HIV-1 was determined using Cf2-Luc cells as previously desc
Entry levels were scored as +++ (> 50,000 luciferase activity units), ++ (between
luciferase activity units), +/ (between 5,000 and 10,000 luciferase activity units),
2001).(Platt et al., 1998, and data not shown), and PBMC have
higher levels of CD4/CCR5 cell surface expression than
MDM (Lewin et al., 1996; Ometto et al., 1999; Wang et al.,
2002, and data not shown). Therefore, the results also raise
the possibility that the diminished M-tropism by early R5
viruses may, at least in part, be attributed to an increased
dependence on CD4 and/or CCR5 expression levels.
Effect of CD4 and CCR5 levels on infection by early and
late R5 viruses
We next investigated whether late, M-tropic R5 viruses
could utilize lower levels of CD4 and/or CCR5 for entry than
early, non-M-tropic R5 viruses. Cf2-Luc cells were cotrans-
fected with increasing amounts of CD4- and CCR5-expres-
sing plasmid to create 16 populations of cells transiently
expressing different amounts of either receptor, as described
in previous studies (Gorry et al., 2001, 2002a). A linear
relationship was found between the levels of CD4 and CCR5
expression and the amount of CD4- and CCR5-expressing
plasmid used for transfection (Fig. 2), similar to previous
studies (Gorry et al., 2001, 2002a; Martin et al., 2001; Shieh
et al., 2000). In the 16 populations, the mean fluorescence
intensity of CD4 remained constant when CCR5 levels were
varied (Fig. 2A), and the mean fluorescence intensity of
CCR5 remained constant when CD4 levels were varied (Fig.
2B). The ability of early and late R5 viruses to infect the 16-
cell populations was examined (Fig. 3). The M-tropic ADA
virus was used as a control. The infectivity of ADA, early,
and late R5 viruses was equivalent when high levels of both
CD4 and CCR5 were expressed. Late R5 viruses and ADA
could infect cells expressing low levels of CD4 or CCR5
(Figs. 3A and C). However, the infectivity of late R5 viruses
and ADA mediated by low levels of CD4 or CCR5 was
generally dependent on the presence of medium or highCXCR4 CX3CR1 Gpr1 Gpr15 Strl33 Apj
+++     +
 +/ +/ + + 
+++     +
     
     
     
     
     
     
     
     
ribed (Churchill et al., 2004; Gorry et al., 2001, 2002b; Lawson et al., 2004).
30,000 and 50,000 luciferase activity units), + (between 10,000 and 30,000
or  (< 5,000 luciferase activity units) as previously described (Gorry et al.,
Fig. 1. Replication kinetics. MDM, PBMC, or JC53 cells were infected with equivalent amounts of each virus as described in Materials and methods, and
cultured for 27 (MDM, PBMC) or 10 days (JC53). HIV-1 production in culture supernatants was measured by RT assays. Data are expressed as means from
duplicate infections. Error bars represent standard deviations. Results are representative of three independent experiments. For experiments using MDM and
PBMC, each independent experiment was performed using cells obtained from different donors.
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tropic R5 viruses (Kuhmann et al., 2000; Platt et al., 1998).
In contrast, early R5 viruses required high levels of both
CD4 and CCR5 expression for infection (Fig. 3B). There-
fore, late M-tropic R5 viruses have reduced dependence on
both CD4 and CCR5 levels for infection compared to early,
non-M-tropic R5 viruses.
Transduction of MDM with retroviral vectors to modulate
CD4/CCR5 expression
MDM were transduced with pSIvec1DenvhuCD4 to
overexpress CD4 or with pSIvec1DenvhuCCR5 to over-express CCR5. Control cultures were transduced with
pSIvec1DenvGFP to express GFP or mock transduced with
pSIvec1DenvEmpty. Thirty-six percent of MDM were
effectively transduced, as determined by GFP expression
(Fig. 4A). Mock-transduced MDM expressed low levels of
CD4 on 84% of cells whereas CCR5 was expressed at low
levels on only 13% of cells, and 12% of mock-transduced
MDM were dually positive for both CD4 and CCR5 (Fig.
4B). Similar results were obtained using untransduced
MDM and CD4-transduced MDM (data not shown). Thus,
transduction of MDM with CD4-expressing vectors did not
result in a further increase in CD4 expression levels.
Transduction of MDM with CCR5-expressing vectors
Fig. 2. CD4 and CCR5 expression in transfected Cf2-Luc cells. Cf2-Luc
cells were cotransfected with 0, 0.05, 0.5, or 5.0 Ag of CD4-expressing
plasmid and 0, 0.05, 0.5, or 5.0 Ag of CCR5-expressing plasmid to create
16 populations of cells which were analyzed for surface expression of CD4
(A) or CCR5 (B) by flow cytometry. Results are representative of two
independent experiments.
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percentage of MDM staining positive for CCR5 and an
approximately 2-fold increase in mean fluorescence inten-
sity of CCR5 (Fig. 4B), resulting in 51% of CCR5-
transduced MDM dually positive for both CD4 and
CCR5. Thus, transduction of MDM with CCR5-expressing
vectors resulted in an increase in CCR5 expression levels
and an increase in the fraction of MDM that are potentially
susceptible to HIV-1 entry.
Effect of CCR5 overexpression on HIV-1 replication in
MDM
To determine whether the low level of CCR5 expression
on MDM contributes to the diminished M-tropism by earlyR5 viruses, the replication kinetics of early and late R5
viruses was compared in MDM transduced with GFP or
CCR5. Replication of early and late R5 viruses in GFP-
transduced MDM (Figs. 5A and C) was similar to that in
mock-transduced and -untransduced MDM (Figs. 1D and G,
and data not shown). Transduction of MDM with CCR5 did
not enhance replication of the late, M-tropic R5 viruses
(Figs. 5C and D), but led to variable increases in replication
of the early, non-M-tropic R5 viruses (Figs. 5A and B).
NB27, which consistently replicated to low levels in GFP-
transduced and -untransduced MDM, achieved levels of
replication similar to late R5 viruses in CCR5-transduced
MDM. In contrast, NB23, NB24, and NB25, which were
consistently unable to replicate to detectable levels in GFP-
transduced or -untransduced MDM, achieved only marginal
levels of replication in CCR5-transduced MDM. These
studies demonstrate that low CCR5 expression levels on
MDM does not restrict replication of late, M-tropic R5
viruses, but is at least one bottleneck for productive
infection by early, non-M-tropic R5 viruses.
Sensitivity of early and late R5 viruses to entry/fusion
inhibitors
The preceding studies suggest that there may be
differences in the efficiency of Env-CCR5 interactions
between early and late R5 viruses, which may impact
sensitivity to entry/fusion inhibitors. We therefore measured
the sensitivity of early and late R5 viruses to inhibition by
TAK-779 and T-20 as described in Materials and methods.
The 50% inhibitory concentrations (IC50) and IC90 are
summarized in Table 2. A nonparametric Mann–Whitney U
test showed that there was a significant increase in the IC50
and IC90 for TAK-779 (P < 0.05) and in the IC50 for T-20
(P < 0.05) against late R5 viruses compared with early R5
viruses. The differences in IC90 for T-20 between early and
late R5 viruses were found not to be statistically significant
(P = 0.19). Thus, late, M-tropic R5 viruses have reduced
sensitivity to inhibition by TAK-779 and T-20 compared to
early, non-M-tropic R5 viruses.
Sensitivity of early and late R5 viruses to antibody
neutralization
We next measured the sensitivity of early and late R5
viruses to neutralization by MAbs IgG1b12, 2F5, and 2G12,
and the polyclonal antibody HIV-Ig as described in
Materials and methods. The IC50 and IC90 are summarized
in Table 3. IgG1b12 neutralized the infectivity of all viruses,
and a nonparametric Mann–Whitney U test showed that
there was a significant decrease in the IC50 and IC90 for
IgG1b12 against late R5 viruses compared with early R5
viruses (P < 0.05). 2F5 and 2G12 neutralized the infectivity
of a subset of early and late R5 viruses and HIV-Ig
neutralized the infectivity of all viruses, but the differences
in IC50 and IC90 for 2F5, 2G12, and HIV-Ig between early
Fig. 3. Effect of CD4 and CCR5 levels on infection by early and late R5 viruses. Cf2-Luc cells were cotransfected with 0, 0.05, 0.5, or 5.0 Ag of CD4-
expressing plasmid and 0, 0.05, 0.5, or 5.0 Ag of CCR5-expressing plasmid to create 16 populations of cells expressing either no, low, medium, or high levels
of CD4 together with no, low, medium, or high levels of CCR5, as described previously (Gorry et al., 2001, 2002a; Martin et al., 2001; Shieh et al., 2000). Each
cell population was infected with equivalent amounts of ADA (A), early R5 viruses (B), or late R5 viruses (C) as described in Materials and methods. Cell
lysates were prepared at 48 h post-infection and assayed for luciferase activity. Results are representative of three independent experiments.
L. Gray et al. / Virology 337 (2005) 384–398 389and late R5 viruses were found not to be statistically
significant (P > 0.08). Thus, late, M-tropic R5 viruses
displayed increased sensitivity to neutralization by IgG1b12
compared to early, non-M-tropic R5 viruses.Discussion
In this study, we used a panel of early and late R5 HIV-1
viruses to investigate phenotypic characteristics that were
associated with M-tropism and R5 HIV-1 pathogenesis. The
early and late R5 viruses used in this study fell into two
distinct phenotypes: late, M-tropic R5 viruses have reduced
dependence on CD4/CCR5 levels for entry; whereas early,
non-M-tropic R5 viruses require comparatively higher
levels of CD4/CCR5 for entry. Limiting levels of CCR5
expression on MDM was at least partially responsible for
the diminished M-tropism by early R5 viruses. Therefore,
decreasing the dependence on CD4/CCR5 levels for entry
may be one mechanism by which R5 viruses acquire or
enhance tropism for macrophages. The phenotypic differ-
ences observed between early non-M-tropic and late M-tropic R5 viruses are likely to involve changes in the Env
glycoproteins, which enhance Env-CCR5 interactions. This
interpretation is supported by previous studies, which
showed that late R5 viruses have decreased sensitivity to
inhibition by the h-chemokine RANTES compared to early
R5 viruses (Jansson et al., 1996, 1999; Koning et al., 2003),
and by a more recent study which linked decreased
RANTES sensitivity by late R5 viruses to alterations in
the mode and efficiency of CCR5 usage by gp120 (Karlsson
et al., 2004). In the present study, we further these findings
by showing that a panel of late M-tropic R5 viruses has
decreased sensitivity to the entry inhibitor TAK-779 and to
the fusion inhibitor T-20 compared to a panel of early non-
M-tropic R5 viruses.
The pathogenesis of R5 HIV-1 is poorly understood.
Results of this study and those of other investigators suggest
that R5 HIV-1 strains may evolve during infection toward
more efficient CCR5 usage (Jansson et al., 1996, 1999;
Karlsson et al., 2004; Koning et al., 2003) (reviewed in
Gorry et al., 2005), although further studies of sequential
virus isolates are required to determine the temporal nature
of this evolution. While we have shown that more efficient
Fig. 4. Expression of GFP, CD4, and CCR5 in transduced MDM. MDM were mock-transduced with pSIvec1DEnvEmpty, or transduced with
pSIvec1DEnvGFP or pSIvec1DEnvhuCCR5 to express GFP or CCR5, respectively, as described in Materials and methods. MDM were analyzed by flow
cytometry for the expression of GFP (A), or for the expression of CD4 and CCR5 after staining with PE-conjugated anti-human CCR5 and FITC-conjugated
anti-human CD4 antibodies (B). Values shown in the boxed areas represent the percentage of cells in the respective region of the scatter plot. Results are
representative of two independent experiments using cells obtained from different donors.
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broader sense increased CCR5 usage by late R5 viruses may
also contribute to the CD4+ T cell loss observed in 50–60%
of patients who progress to AIDS while harboring R5 viral
variants. This hypothesis is consistent with previous in vitro
and in vivo studies that showed increased replicative
capacity (Blaak et al., 1998; de Roda Husman et al.,
1999; van ’t Wout et al., 1998) and T cell cytopathicity
(Kwa et al., 2003; Scoggins et al., 2000) by late R5 viruses
compared to early R5 viruses, and consistent also with a
previous study that demonstrated increased apoptosis of
bystander T cells by R5 HIV-1 with increased gp120-
receptor affinity and increased coreceptor binding site
exposure (Holm et al., 2004). However, results of other in
vivo and in vitro studies suggest that the pathogenicity of
R5 strains may also be related to cytokine induction of
increased CCR5 expression (Blaak et al., 2000; Choudhary
et al., 2005). Together, the results of the present study and
those of other investigators suggest that enhanced virus–
receptor interactions and augmented immune activation arelikely to be significant in the pathogenesis of R5 HIV-1
infection.
Late R5 viruses were found to be less sensitive to
inhibition by TAK-779 and T-20 compared to early R5
viruses. Because late R5 viruses require lower levels of
CCR5 for entry compared to early R5 viruses, and since late
R5 viruses are more readily neutralized by the conforma-
tion-dependent MAb IgG1b12 than early R5 viruses, one
interpretation of these findings is that an increase in CCR5
affinity by late R5 Envs may impede the efficacy of both
entry inhibitors. This hypothesis is supported by results of a
number of previous studies that have demonstrated the
following: (i) reduced sensitivity of a neurovirulent R5 virus
with increased Env-CCR5 affinity to inhibition by TAK-779
and another CCR5 inhibitor, SCH-C (Gorry et al., 2002a);
(ii) HIV-1 escape from the CCR5 inhibitor AD101 which
resulted, at least in part, by an increase in the affinity of Env
for CCR5 (Trkola et al., 2002); (iii) increased sensitivity of
the HIV-1 YU2 strain to inhibition by TAK-779 and T-20
when mutations in Env which reduce CCR5 affinity were
Fig. 5. Effect of high CCR5 expression on early and late R5 virus replication in MDM. MDM expressing high levels of CCR5 (B, D) or GFP as a control (A, C)
were infected with equivalent amounts of each early R5 virus (A, B) or late R5 virus (C, D), as described in Materials and methods, and cultured for 27 days.
HIV-1 production in culture supernatants was measured by RT assays. Data are expressed as means from duplicate infections. Error bars represent standard
deviations. Results are representative of two independent experiments using cells obtained from different donors.
Table 3
IC50s and IC90s of Env MAbs and HIV-Ig
L. Gray et al. / Virology 337 (2005) 384–398 391introduced (Reeves et al., 2002, 2004); and (iv) increased
Env-mediated fusion kinetics by Envs with increased CCR5
affinity which decreased sensitivity to inhibition by T-20
(Reeves et al., 2002, 2004). Thus, an increase in the affinity
of Env for CCR5 may reduce the sensitivity to entry
inhibitors by at least two mechanisms: (i) by direct
competition between small molecule inhibitors of CCR5
for CCR5 binding, and (ii) by increasing the rate of fusion
limiting the opportunity for fusion inhibitors to be effective.
Further studies of CCR5 affinity by Envs cloned from early
and late R5 viruses are required to determine whether
changes in Env-CCR5 affinity by primary R5 viruses affect
the sensitivity to entry inhibitors.Table 2
IC50s and IC90s of HIV-1 entry inhibitors TAK-779 and T-20
Inhibitor Early R5 viruses Late R5 viruses
NB23 NB24 NB25 NB27 NB2 NB6 NB7 NB8
TAK-779 IC50* 0.78 1.8 2.4 2.5 15 12 28 25
IC90* 33 40 43 40 68 52 >100 98
T-20 IC50* 0.88 <0.1 0.6 2 7.5 10 6.5 13
IC90 17 2.6 10 >100 70 70 70 >100
IC50 and IC90 values of entry inhibitors TAK-779 (AM) and T-20 (Ag/ml)
for infection of Cf2-Luc cells expressing CD4 and CCR5 by early and late
R5 viruses were calculated as described in Materials and methods.
* P < 0.05 for the difference in inhibitory concentrations between early
and late R5 viruses by a nonparametric Mann–Whitney U test.Late R5 viruses were more sensitive than early R5
viruses to neutralization by IgG1b12, and there was a trend
towards increased sensitivity of late R5 viruses to neutral-
ization by 2F5, although this trend did not reach statistical
significance. These results are strikingly similar to those of
previous studies demonstrating that R5 Env clones from the
neurovirulent UK1-br HIV-1 strain with increased CCR5
affinity were unusually sensitive to neutralization by
IgG1b12, 2F5, and to the tetrameric CD4-IgG2 moleculeAntibody Early R5 viruses Late R5 viruses
NB23 NB24 NB25 NB27 NB2 NB6 NB7 NB8
IgG1b12 IC50* 25 12 3.2 7 0.16 <0.1 2 2.8
IC90* >100 68 18 >100 1.4 6.5 10 8.1
2F5 IC50 R 15 12 R 2.6 0.9 6.1 R
IC90 R >100 77 R 80 52 >100 R
2G12 IC50 R R 30 R R 34 R R
IC90 R R >100 R R >100 R R
HIV-Ig IC50 54 19 <10 62 46 74 160 200
IC90 2800 410 730 8500 1000 750 3500 3400
IC50 and IC90 values of Env MAbs and HIV-Ig (Ag/ml) for infection of Cf2-
Luc cells expressing CD4 and CCR5 by early and late R5 viruses were
calculated as described in Materials and methods. R, resistant to
neutralization.
* P < 0.05 for the difference in inhibitory concentrations between early
and late R5 viruses by a nonparametric Mann–Whitney U test.
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that a CD4-independent variant of HIV-1 ADA (ADA197N/
K) was unusually sensitive to neutralization by IgG1b12,
2F5, and sCD4 but not by the anti-CCR5 MAb 2D7
(Kolchinsky et al., 2001). In the latter study, the increased
neutralization sensitivity to MAbs and sCD4 was thought to
result from an increase in the exposure of the CCR5 binding
domain and its associated antibody epitopes. The results of
the present study suggest that late R5 virus Envs may have
structural features that resemble those in HIV-1 UK1-br and
ADA197N/K. The association between M-tropism, CD4/
CCR5 dependence, and neutralization sensitivity by R5
HIV-1 strains demonstrated here is also similar to that found
in a previous study of SIV strains, which showed a
correlation between viral growth in cultures of alveolar
macrophages, decreased CD4 dependence, and increased
sensitivity to antibody neutralization (Means et al., 2001).
Late, M-tropic R5 viral variants that have increased
sensitivity to antibody neutralization may be able to
replicate and persist in vivo during late stages of HIV-1
infection when the humoral immune response is waning
(reviewed in Gorry et al., 2005). This hypothesis is
supported by recent evidence which suggests that neutral-
ization-sensitive R5 HIV-1 strains may be preferentially
transmitted heterosexually (Derdeyn et al., 2004). Reduced
selection pressure from antibodies may allow the evolution
of R5 variants with increased CD4/CCR5 interactions,
similar to that which occurs in immune privileged anatom-
ical sites such as the brain (Gorry et al., 2001, 2002a; Martin
et al., 2001; Peters et al., 2004; Shieh et al., 2000; Strizki et
al., 1996). This would be consistent with a long standing
concept that the protection of HIV-1 from neutralizing
antibodies carries the price of a less efficient interaction with
it’s entry receptors (Moore and Ho, 1995).
Although early R5 viruses could replicate efficiently in
JC53 cells and PBMC and were highly infectious for Cf2-
Luc cells when engineered to express high levels of CD4/
CCR5, none were able to replicate efficiently in MDM, and
only NB27 could replicate to levels comparable to late R5
viruses when CCR5 was overexpressed on MDM. In
contrast, only marginal increases in levels of replication
could be detected in MDM cultures infected with early R5
viruses NB23, NB24, or NB25 when CCR5 was over-
expressed. The fact that NB27 was able to replicate to low
levels in untransduced MDM suggests that this virus may
exist in a conformation that renders it more responsive to
increases in CCR5 expression levels for entry into MDM.
Alternatively, it is possible that infection of MDM may
select for replication of a minor variant in the NB27 viral
quasi-species which is enhanced by increasing CCR5
expression. The reasons underlying the discrepant infectiv-
ities of early R5 viruses NB23, NB24, and NB25 for
infection of CD4/CCR5-expressing Cf2-Luc cells and
CCR5-expressing MDM are unclear. Further studies are
required to determine why increasing CCR5 expression
levels on MDM was insufficient to rescue M-tropism bythese early R5 viruses, but possibilities include limiting
CD4 levels (Bannert et al., 2000; Mori et al., 2000), further
post-entry blocks; for example, those exerted prior to
(Cunningham et al., 2000; Naif et al., 1999) or at reverse
transcription (Eisert et al., 2001; Neil et al., 2001; Sonza et
al., 1996; Triques and Stevenson, 2004), or differences in
CCR5 conformation (Doms, 2000; Hill et al., 1998) and/or
post-translational modifications such as sulfation (Farzan et
al., 1999) or O-linked glycosylation (Carlsson et al., 1986;
Farzan et al., 1999; Fukuda et al., 1986) that exist between
macrophages and other susceptible cell types. Differences in
the stoichiometry and physical relationship of CD4/CCR5
expressed on Cf2-Luc cells compared to MDM may also be
a bottleneck for infection of MDM by R5 viruses (Kuhmann
et al., 2000; Platt et al., 1998). Other cell-specific factors
(Doms, 2000), as well as viral factors such as Nef, could
also affect the level of M-tropism by R5 viruses (Balliet et
al., 1994; Miller et al., 1994).
In conclusion, reduced CD4/CCR5 dependence is a
phenotype of R5 HIV-1 associated with M-tropism, R5
HIV-1 pathogenesis, and reduced sensitivity to inhibition by
T-20 and TAK-779. T-20 is currently used as an anti-HIV-1
therapeutic, and several CCR5 inhibitors are in clinical trials
or preclinical development. Whether late R5 viral variants
with reduced CD4/CCR5 dependence will impede therapy
by T-20 or CCR5 inhibitors remains to be determined by
clinical studies. However, these findings underscore the
importance of inhibiting late emerging, M-tropic R5 HIV-1
variants in the design of antiretroviral strategies aimed at
inhibiting HIV-1 entry.Materials and methods
Virus isolates
HIV-1NL4-3 and HIV-189.6 virus stocks were produced by
transfection of 293T cells with proviral plasmid DNA
(Adachi et al., 1986; Collman et al., 1992) by the calcium
phosphate method (Gorry et al., 1998). HIV-1ADA virus
stocks (Gendelman et al., 1988) were prepared from
supernatants of infected PBMC as described previously
(Gorry et al., 2001). A detailed characterization of the
primary HIV-1 viruses used in this study including Env V1,
V2, and V3 sequence and heteroduplex mobility assay
analysis of viral diversity, and clinical characteristics of the
subjects from whom they were isolated, is described in a
previous study (Li et al., 1999). Briefly, early HIV-1 viruses
NB23, NB24, and NB25 were isolated from PBMC of
individuals with CDC category II disease (asymptomatic
infection) with CD4 counts of >500 cells/Al. Early virus
NB27 was isolated from PBMC of an individual with CDC
category I disease (acute seroconversion) with CD4 count of
>750 cells/Al. Late viruses NB2, NB6, NB7, and NB8 were
isolated from PBMC of individuals with CDC category IV
disease (AIDS) and CD4 counts of <50 cells/Al. Virus
L. Gray et al. / Virology 337 (2005) 384–398 393stocks were quantified by reverse transcriptase (RT) assay
using [33P]dTTP incorporation as described previously
(Gorry et al., 1998), filtered through 0.45 Am pore size
filters and stored at 80 -C.
Cells
PBMC were purified from blood of healthy HIV-1-
negative donors, stimulated with 5 Ag/ml of phytohemag-
glutinin (PHA) (Sigma, St. Louis, MO) for 3 days, and
cultured in RPMI 1640 medium supplemented with 10%
(vol/vol) fetal calf serum (FCS), 100 Ag/ml of penicillin and
streptomycin, and 20 U/ml of interleukin-2 (IL-2) (Roche,
Basel, Switzerland). MDM were purified from PBMC by
plastic adherence and cultured for 5 days in RPMI 1640
medium supplemented with 10% (vol/vol) human AB+
serum, and 100 Ag/ml of penicillin and streptomycin. Cf2-
Luc cells (Etemad-Moghadam et al., 2000), derived from
the Cf2th canine thymocyte cell line (Choe et al., 1996),
stably express the luciferase gene under the control of the
HIV-1 long terminal repeat and were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10%
(vol/vol) FCS, 100 Ag/ml of penicillin and streptomycin,
and 0.7 mg/ml of G418 (Gibco BRL, Gaithersburg, MD).
JC53 cells are derived from the HeLa cell line and stably
express high levels of CD4 and CCR5 on the cell surface
(Platt et al., 1998), and were cultured in DMEM supple-
mented with 10% (vol/vol) FCS, and 100 Ag/ml of penicillin
and streptomycin.
Coreceptor usage
Coreceptor usage by primary HIV-1 isolates was
determined using Cf2-Luc cells expressing CD4 alone,
or expressing CD4 together with CCR2b, CCR3, CCR5,
CCR8, CXCR4, CX3CR1, Gpr1, Gpr15, Strl33, or Apj,
as described previously (Churchill et al., 2004; Gorry et
al., 2001, 2002b; Lawson et al., 2004). Briefly, Cf2-Luc
cells were transfected with 10 Ag of plasmid pcDNA3-
CD4 and 20 Ag of plasmid pcDNA3 containing HIV-1
coreceptor using the calcium phosphate method, and
infected 48 h later by incubation with 1  106 33P cpm
RT units of HIV-1 in the presence of 2 Ag/ml of
Polybrene (Sigma). After overnight infection, virus was
removed and the cells were cultured for an additional 48
h prior to lysis in 200 Al of cell lysis buffer (Promega,
Madison, WI). Cell lysates were cleared by centrifugation
and assayed for luciferase activity (Promega) according to
the manufacturer’s protocol.
HIV-1 replication kinetics
Five hundred thousand PHA-activated PBMC were
infected in 48-well tissue culture plates by incubation with
1  106 33P cpm RT units of virus supernatant in a volume
of 250 Al for 3 h at 37 -C, as described previously (Churchillet al., 2004). Virus was then removed, and PBMC were
washed 3 times with phosphate-buffered saline (PBS) and
cultured in medium containing 20 U/ml of IL-2 for 27 days.
Fifty percent medium changes were performed twice
weekly, and supernatants were tested for HIV-1 replication
by RT assays. MDM were isolated from PBMC by plastic
adherence and allowed to mature for 5 days prior to
infection, as described previously (Gorry et al., 2001). At
approximately 90% confluence in 48-well tissue culture
plates, virus equivalent to 1  106 33P cpm RT units in a
volume of 250 Al was allowed to adsorb to the cell
monolayers for 3 h at 37 -C. Virus was then removed,
and cells were rinsed 3 times with PBS prior to addition of
500 Al of culture medium. Fifty percent medium changes
were performed twice weekly for 27 days, and supernatants
were tested for HIV-1 replication by RT assays. JC53 cells
cultured in 48-well tissue culture plates to approximately
50% confluence were infected by incubation with 1  106
33P cpm RT units of virus supernatant in a volume of 250
Al for 3 h at 37 -C. Virus was then removed, and cells were
rinsed 3 times with PBS prior to addition of 500 Al of
culture medium. Fifty percent medium changes were
performed twice weekly for 14 days, and supernatants were
tested for HIV-1 replication by RT assays.
CD4/CCR5 dependence assay
Cf2-Luc cells were cotransfected with 0, 0.05, 0.5, or 5.0
Ag of plasmid pcDNA3-CD4 and 0, 0.05, 0.5, or 5.0 Ag of
plasmid pcDNA3-CCR5 using the calcium phosphate
method to create 16 populations of cells expressing either
no, low, medium, or high levels of CD4 together with no,
low, medium, or high levels of CCR5, as described
previously (Gorry et al., 2001, 2002a; Martin et al., 2001;
Shieh et al., 2000). The total amount of plasmid DNA used
in each transfection was adjusted to 10 Ag with empty
pcDNA3 plasmid. Under these conditions the cotransfection
efficiency of Cf2-Luc cells is typically 60–70%, as
determined by coexpression of GFP (data not shown).
Transfection of Cf2-Luc cells with pcDNA3-CD4 or
pcDNA3-CCR5 in amounts increasing from 0.05 to 5.0
Ag results in a linear increase in CD4 or CCR5 expression
levels, respectively (Gorry et al., 2001, 2002a). Infection of
Cf2-Luc target cells and measurement of virus infection was
performed as described above.
Retroviral transduction of monocyte-derived macrophages
The envelope-deficient SHIV vectors pSIvec1-
DenvEmpty, pSIvec1DenvGFP, pSIvec1DenvhuCD4, and
pSIvec1DenvhuCCR5 used to transduce MDM with no
protein, GFP, CD4, or CCR5, respectively, have been
described previously (Bannert et al., 2000; Hofmann et al.,
1999). Transducing viruses pseudotyped with vesicular
stomatitis virus G protein were produced by co-transfection
of 293T cells with the pSIvec1Denv vector plus pHCMV-G
L. Gray et al. / Virology 337 (2005) 384–398394and a Rev-expressing plasmid at a ratio of 20:5:5. At 72
h post-transfection, cell supernatants containing transducing
viruses were cleared by centrifugation, filtered through 0.45
Am pore size filters, quantified by RT assays, and stored at
80 -C. Five-day-old MDM at approximately 90%
confluence in 48-well tissue culture plates were transduced
by overnight infection with 2  106 33P RT units of virus in
a volume of 250 Al containing 5 Ag/ml of Polybrene
(Sigma). Virus was removed and cells were rinsed twice
with culture medium prior to culturing for an additional 48
h. Transduced MDM were infected with HIV-1 isolates as
described above, or analyzed for the expression of GFP in
cells or CD4 and CCR5 on the cell surface as described
previously (Gorry et al., 2001).
Virus inhibition studies
The effect of the CCR5 antagonist TAK-779 (Baba et
al., 1999) and fusion inhibitor T-20 on virus infectivity was
assayed using Cf2-Luc cells expressing CD4 and CCR5 as
target cells for infection. Briefly, 2  104 Cf2-Luc target
cells cultured in 48-well tissue culture plates were
incubated for 30 min with a range of concentrations of
TAK-779 (0.01–100 AM) or T-20 (0.01–100 Ag/ml) prior
to infection with 1  106 33P cpm RT units of each HIV-1
isolate in a volume of 250 Al for 3 h at 37 -C. Under these
conditions, Cf2-Luc target cells support equivalent levels
of virus infection by the primary HIV-1 isolates in the
absence of inhibitor (data not shown). Mock-infected
cultures of inhibitor-treated cells were incubated with 250
Al culture medium instead of virus supernatant. The
inoculum was then removed, and cells were rinsed 3 times
with PBS prior to addition of 500 Al of culture medium.
Virus infectivity was measured by assaying luciferase
activity in cell lysates at 72 h post-infection. After
subtracting background luciferase activity of mock-infected
cultures, the amount of luciferase activity in the presence of
an inhibitor was expressed as a percentage of the amount
produced in control cultures containing no inhibitor. The
percent inhibition was calculated by subtracting this
number from 100. Inhibition curves were generated using
XLfit software (IDBS, Surrey, UK), and the IC50 and IC90
values were calculated by 4-parameter nonlinear regression.
The differences in inhibitory concentrations between early
and late R5 viruses were analyzed by a nonparametric
Mann–Whitney U test.
Neutralization assays
Human monoclonal antibodies (MAb) against HIV-1
gp120 (IgG1b12 and 2G12) and gp41 (2F5) and the
polyclonal antibody HIV-Ig have been described previously
(Burton et al., 1991, 1994; Muster et al., 1994; Trkola et al.,
1995, 1996). Neutralization of virus infectivity in Cf2-Luc
target cells expressing CD4 and CCR5 was assessed by
incubation of virus for 2 h at 37 -C with a range ofconcentrations of each MAb (0.01–100 Ag/ml) or HIV-Ig
(10–10,000 Ag/ml) prior to infection, as previously de-
scribed (Gorry et al., 2002a; Trkola et al., 1995). Infection
of Cf2-Luc target cells, measurement of virus infectivity,
and percent neutralization were calculated as described
above. Inhibition curves were generated using XLfit
software (IDBS, Surrey, UK), and IC50 and IC90 values
were calculated by 4-parameter nonlinear regression. The
differences in inhibitory concentrations between early and
late R5 viruses were analyzed by a nonparametric Mann–
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